Cumulative treatment outcomes prevalence rates for patients in ART treatment from year 2020 to 2022 for study participant in Bauchi State. by Ekerette Emmanuel Udoh (7326194)

Subjects:

Analysis of randomized controlled trials stratified based on treatment duration. by Solima Sabeel (9545738)

Subjects:

S8 File - by Martha R. Smith (20410184)

“…Five of the 11 studies that evaluated hepatic steatosis reported an absolute decrease of 1% to 3%. In the nine studies that evaluated liver chemistry, no significant changes were observed.…”

Study populations of included studies. by Martha R. Smith (20410184)

“…Five of the 11 studies that evaluated hepatic steatosis reported an absolute decrease of 1% to 3%. In the nine studies that evaluated liver chemistry, no significant changes were observed.…”

Future research directions. by Martha R. Smith (20410184)

“…Five of the 11 studies that evaluated hepatic steatosis reported an absolute decrease of 1% to 3%. In the nine studies that evaluated liver chemistry, no significant changes were observed.…”

PRISMA flow diagram. by Martha R. Smith (20410184)

“…Five of the 11 studies that evaluated hepatic steatosis reported an absolute decrease of 1% to 3%. In the nine studies that evaluated liver chemistry, no significant changes were observed.…”

S9 File - by Martha R. Smith (20410184)

“…Five of the 11 studies that evaluated hepatic steatosis reported an absolute decrease of 1% to 3%. In the nine studies that evaluated liver chemistry, no significant changes were observed.…”

S7 File - by Martha R. Smith (20410184)

“…Five of the 11 studies that evaluated hepatic steatosis reported an absolute decrease of 1% to 3%. In the nine studies that evaluated liver chemistry, no significant changes were observed.…”

Participant characteristics of included studies. by Martha R. Smith (20410184)

“…Five of the 11 studies that evaluated hepatic steatosis reported an absolute decrease of 1% to 3%. In the nine studies that evaluated liver chemistry, no significant changes were observed.…”

Trends in overall global leukemia burden, 1990-2021. by Chengjun Hu (588206)

Subjects:

Moderate correlation (R² = 0.136 p = .0085) between Medicare prescriptions per 1,000 persons and the percentage of white population among the fifty US states. by Luke R. Cavanah (19022435)

Subjects:

Projected global leukemia burden, 1990-2050. by Chengjun Hu (588206)

Subjects:

Large state-wide variation (8.6-fold) in number of clozapine prescriptions per thousand Medicare Part D enrollees in 2018 ^a indicates ≥1.50 SD (17.9) from the mean (32.9... by Luke R. Cavanah (19022435)

Subjects:

Map of the overall global burden of leukemia, 1990-2021. by Chengjun Hu (588206)

Subjects:

Project the global leukemia burden in patients younger and older than 20 years. by Chengjun Hu (588206)

Subjects:

Leukemia ASDR and SDI for 204 countries and territories in 2021. by Chengjun Hu (588206)

Subjects:

Map of the overall global leukemia burden status, 1990-2021. by Chengjun Hu (588206)

Subjects:

Frontier analysis based on SDI and age-standardized leukemia ASDR per 100,000 population from 1990 to 2021. by Chengjun Hu (588206)

Subjects:

Strong correlation (R² = 0.734 p < .0001) between Medicare prescriptions per 1,000 persons and Medicaid prescriptions per 1,000 persons among the fifty US states in 2019... by Luke R. Cavanah (19022435)

Subjects:

Large state-wide variation (11.1-fold) in number of clozapine prescriptions per thousand Medicare Part D enrollees in 2015 ^a indicates ≥1.50 SD (20.2) from the mean (36.... by Luke R. Cavanah (19022435)

Subjects: